EUVIMEDEUVIMED entdecken
Open Access

The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis

Handan Yarkan Tuğsal, Gökçe Kenar Artin, Gerçek Can, Sedat Çapar, Berrin Zengin, Servet Akar, Hüseyin Ediz Dalkiliç, Abdurrahman Soner Şenel, Süleyman Serdar Koca, Berna Göker, Ayten Yazici, Güzide Nevsun İnanç und 3 weitere

Turkish Journal of Medical Sciences · 01.01.2023 · 53 (4) · 970-978

DOI: 10.55730/1300-0144.5661 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 01.01.2023. Verfasst von Handan Yarkan Tuğsal und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkiye. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aim: To investigate the impact of smoking on disease activity, treatment retention, and response in patients with ankylosing spondylitis (AS) treated with their first tumor necrosis factor-α inhibitor (TNFi). Materials and methods: AS patients who started their first TNFi treatment for the active axial disease (BASDAI ≥ 4) from TURKBIO Registry were included. Treatment response of smoker (current and ex-smokers) and nonsmoker (never smoker) patients were primarily evaluated as achievement of BASDAI50 or improvement in BASDAI at least 20 mm at 3 months and 6 months compared to baseline.

Results

There were 322 patients with AS (60% male, 59% smoker, mean age: 38.3 years). The median follow-up time was 2.8 years (Q1- Q3: 1.3-3.8), and disease duration was 3.5 years (Q1-Q3: 0.7-8.2). Smokers had male predominance (p < 0.001), lower ESR (p = 0.03), higher BASDAI (p = 0.02), BASFI (p = 0.05), HAQ-AS (p = 0.007), and ASDAS-CRP (p = 0.04) compared with nonsmokers at baseline. In the multivariate analysis, male gender [OR 2.7 (95%CI 1.4-5), p = 0.002], and concomitant conventional synthetic disease-modifying antirheumatic drug use [OR 2.4 (95%CI 1.1-5.2), p = 0.03] were associated with better treatment response. There was an association of male gender [HR 2.4 (95%CI 1.6-3.7), p < 0.001], older age (≥ 30years) [HR 1.8 (95%CI 1.1-2.8), p = 0.01], and response to treatment [HR 1.8 (95%CI 1.2-2.9), p = 0.008] with better treatment retention. No impact of smoking status was found on treatment retention and response in univariate and multivariate analyses.

Conclusion

This study suggested that smoking was associated with poorer patient-reported outcomes in biologic naïve AS patients initiating their first TNFi treatment, but it had no impact on the TNFi treatment response and retention rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spondylitis, AnkylosingAntirheumatic AgentsHumansMaleAdultFemaleTumor Necrosis Factor-alphaTreatment OutcomeSmokingImmunologic FactorsSeverity of Illness Index

Stichwörter der Autor:innen

Ankylosing spondylitisregistrysmokingtreatment responsetumor necrosis factor-alpha inhibitor

Substanzen

Tumor Necrosis Factor-alphaAntirheumatic AgentsImmunologic Factors

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkiye.
  • Department of Statistics, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkiye.
  • Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Katip Çelebi University, İzmir, Turkiye.
  • Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Uludağ University, Bursa, Turkiye.
  • Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkiye.
  • Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fırat University, Elazığ, Turkiye.

Zitieren

APA

Tuğsal, H. Y., Artin, G. K., Can, G., Çapar, S., Zengin, B., Akar, S., Dalkiliç, H. E., Şenel, A. S., Koca, S. S., Göker, B., Yazici, A., İnanç, G. N., Ellidokuz, H., Akkoç, N., & Önen, F. (2023). The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. Turkish Journal of Medical Sciences, 53(4), 970-978. https://doi.org/10.55730/1300-0144.5661

Vancouver

Tuğsal HY, Artin GK, Can G, Çapar S, Zengin B, Akar S, et al. The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis. Turkish Journal of Medical Sciences. 2023;53(4):970-978. doi:10.55730/1300-0144.5661

BibTeX
@article{Tusal2023,
  author = {Tuğsal, Handan Yarkan and Artin, Gökçe Kenar and Can, Gerçek and Çapar, Sedat and Zengin, Berrin and Akar, Servet and Dalkiliç, Hüseyin Ediz and Şenel, Abdurrahman Soner and Koca, Süleyman Serdar and Göker, Berna and Yazici, Ayten and İnanç, Güzide Nevsun and Ellidokuz, Hülya and Akkoç, Nurullah and Önen, Fatoş},
  title = {The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis},
  journal = {Turkish Journal of Medical Sciences},
  year = {2023},
  volume = {53},
  number = {4},
  pages = {970--978},
  doi = {10.55730/1300-0144.5661}
}
Kostenlos starten →